All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019

X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Freeline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

WRIB

Participation Not Confirmed

Update your events

Freeline receives Orphan Drug Designation from the European Commission

Contact the Supplier

Lead Product(s): FLT190

Therapeutic Area: Genetic Disease

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

A 3 to 4-fold increase in plasma ?GLA activity was achieved by week 4 and sustained through the data cutoff at week 20.

Freeline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

WRIB

Participation Not Confirmed

Update your events

Freeline presents data on its AAV-based gene therapies

Contact the Supplier

Lead Product(s): FLT190

Therapeutic Area: Genetic Disease

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 12, 2020

Details:

As of the data cutoff date, there have been no infusion-related adverse events. Two Grade 1 or 2 serious adverse events have been reported in the study.